Agencia Española de Medicamentos y Productos Sanitarios
Parque Empresarial Las Mercedes
Edificio 8
C/Campezo 1,
28022 – Madrid
España
(Reference Member State)

MUTUAL RECOGNITION PROCEDURE

PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT
# Module 1

## Product Summary

<table>
<thead>
<tr>
<th>EU Procedure number</th>
<th>ES/V/0133/001/MR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Name, strength and pharmaceutical form</td>
<td>FLUVEX 50 mg/ml solution for injection for cattle, pigs and horses</td>
</tr>
<tr>
<td>Applicant</td>
<td>S. P. VETERINARIA, S.A.</td>
</tr>
<tr>
<td></td>
<td>Ctra. Reus-Vinyols, Km. 4,1</td>
</tr>
<tr>
<td></td>
<td>Apartado de correos nº 60</td>
</tr>
<tr>
<td></td>
<td>43330 Riudoms (Tarragona)</td>
</tr>
<tr>
<td></td>
<td>España</td>
</tr>
<tr>
<td>Active substance(s)</td>
<td>Flunixin (as flunixin meglumine)</td>
</tr>
<tr>
<td>ATC Vet code</td>
<td>QM01AG90</td>
</tr>
<tr>
<td>Target species</td>
<td>Cattle, horses and pigs.</td>
</tr>
</tbody>
</table>

### Indication for use

**Cattle**
Prescribed for the control of acute inflammation and pyrexia associated to bovine respiratory disease.

**Horses**
Prescribed for alleviation of inflammation and pain associated with acute and chronic musculo-skeletal disorders, and for visceral pain associated to colic.

**Pigs**
Recommended as adjunctive therapy in the treatment of swine respiratory diseases an adjunct to therapy to reduce clinical signs, of metritis-mastitis agalactia syndrome (MMA) in sows.
The Summary of Product Characteristics (SPC) for this product is available on the Heads of Medicines Agencies website (http://www.hma.eu).
PUBLIC ASSESSMENT REPORT

<table>
<thead>
<tr>
<th>Legal basis of original application</th>
<th>Mutual Recognition application in accordance with Article 13.1 of Directive 2001/82/EC as amended.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Date of completion of the original mutual recognition procedure</td>
<td>Day 90: 25/11/2009</td>
</tr>
<tr>
<td>Date product first authorised in the Reference Member State (MRP only)</td>
<td>07/06/2007</td>
</tr>
<tr>
<td>Concerned Member States for original procedure</td>
<td>BE, BG, EL, IT, LU, NL, PL, PT and RO.</td>
</tr>
</tbody>
</table>

I. SCIENTIFIC OVERVIEW

For public assessment reports for the first authorisation in a range:

The product is produced and controlled using validated methods and tests, which ensure the consistency of the product released on the market.

It has been shown that the product can be safely used in the target species; the slight reactions observed are indicated in the SPC.

The product is safe for the user, the consumer of foodstuffs from treated animals and for the environment, when used as recommended. Suitable warnings and precautions are indicated in the SPC.

The efficacy of the product was demonstrated according to the claims made in the SPC.

The overall risk/benefit analysis is in favour of granting a marketing authorisation.
II. QUALITY ASPECTS

A. Composition

The product contains 50 mg/ml of flunixin meglumine and excipients propylene glycol, diethanolamine, phenol, disodium edetate, sodium formaldehyde sulfoxylate, HCl and water for injection.

The container/closure system are sterile translucent polypropylene suitable for parenteral solutions (Eur. Ph.: 01/2008:30106), of 50 and 100 ml, provided with grey rubber stoppers of bromobutyl, formulation PH 4001A and metallic aluminium capsules with blue flip-off ring.

The particular of the containers and controls performed are provided and conform to the regulation.

The choice of the presence of preservative is justified.

The product is an established pharmaceutical form and its development is adequately described in accordance with the relevant European guidelines.

B. Method of Preparation of the Product

The product is manufactured fully in accordance with the principles of good manufacturing practice from a licensed manufacturing site.

Process validation data on the product have been presented in accordance with the relevant European guidelines.

C. Control of Starting Materials

The active substance is flunixin meglumine, an established active substance described in the European Pharmacopoeia. The active substance is manufactured in accordance with the principles of good manufacturing practice.

The active substance specification is considered adequate to control the quality of the material.

Batch analytical data demonstrating compliance with this specification have been provided.

The applicant justifies the quality of the raw material by means of an Active Substance Master File (ASMF Number FM/669/00 in Spain).

Disodium edetate, propylene glycol, phenol, water for injections in bulk and hydrochloric acid concentrated comply with the monographs number 01/2005:0232; 01/2005:0430; 01/2005:0631; 01/2005:0169 and 01/2005:0002 of the European Pharmacopoeia, respectively. Diethanolamine and
sodium formaldehyde sulfoxylate comply with the monographs number USP 23-NF 18, p.2241 and 2302 respectively.

**D. Specific Measures concerning the Prevention of the Transmission of Animal Spongiform Encephalopathies**

Scientific data and/or certificates of suitability issued by the EDQM have been provided and compliance with the Note for Guidance on Minimising the Risk of Transmitting Animal Spongiform Encephalopathy Agents via Human and Veterinary Medicinal Products has been satisfactorily demonstrated.

**E. Control on intermediate products**

The tests performed during production are described and the results of 3 consecutive runs, conforming to the specifications, are provided.

**F. Control Tests on the Finished Product**

The finished product specification controls the relevant parameters for the pharmaceutical form. The tests in the specification, and their limits, have been justified and are considered appropriate to adequately control the quality of the product.

Satisfactory validation data for the analytical methods have been provided.

Batch analytical data from the proposed production site have been provided demonstrating compliance with the specification.

**G. Stability**

Stability data on the active substance have been provided in accordance with applicable European guidelines, demonstrating the stability of the active substance when stored under the approved conditions.
III. SAFETY AND RESIDUES ASSESSMENT

As this is a generic application according to Article 13, results of safety tests are not required. The product Fluvex has the same qualitative and quantitative composition as the reference product Finadyn solution for injection (Schering Plough, S.A.).

IIIA Safety Testing

Pharmacological Studies

Flunixin meglumine acts as a reversible non-selective inhibitor of cyclo-oxygenase (COX), an enzyme that converts arachidonic acid to unstable cyclic endoperoxides, which are transformed into prostaglandins, prostacyclines and thromboxanes.

Flunixin meglumine administered by intravenous route to cattle and horses, as a single dose of 2.2 mg/kg and 1.1 mg/kg respectively leads to an elimination half-life of 4 hours and 2 hours respectively.

Bioequivalence with the reference product Finadyne solution for injection has been demonstrated in sows after intramuscular administration. For cattle and horses, no bioequivalence studies have been performed and it is justified as it fulfils point 4.a) of the exemptions of the guideline EMEA/CVMP/016/00 for the conduct of bioequivalence studies for veterinary medicinal products.

Toxicological Studies

As this is a generic application according to Article 13, results of toxicological tests are not provided because evidences were already proved for the reference product.

User Safety

The applicant has provided a user safety assessment in compliance with the relevant guideline which shows that Fluvex is safe for the user when is used in accordance with label recommendations.

Warnings and precautions as listed on the product literature are adequate to ensure safety to users of the product.

Ecotoxicity

The applicant provided a first phase environmental risk assessment in compliance with the relevant guideline which showed that no further assessment is required. Warnings and precautions as listed on the product literature are adequate to ensure safety to the environment when the product is used as directed.

IIIB Residues documentation
Residue Studies

The applicant has conducted a residue depletion study to determine flunixin meglumine residues in injection site tissues samples obtained from sows.

In case of bovine and equine, because the route of administration is intravenous, the applicant is not required to provide the results of residues studies because all these data are in the documentation that supports the marketing authorization of the reference product, FINADYN® solution for injection (SCHERING PLOUGH S.A.).

The analytical method was HPLC with UV detection. The method was fully validated.

MRLs

Flunixin meglumine is listed in Annex I of Council Regulation 470/2009. The marker substance is 5-hydroxy flunixin for milk and flunixin for muscle, liver, kidney and fat.

MRLs are listed below:

<table>
<thead>
<tr>
<th>Pharmacologically active substance(s)</th>
<th>Marker residue</th>
<th>Animal species</th>
<th>MRLs</th>
<th>Target tissue</th>
</tr>
</thead>
<tbody>
<tr>
<td>Flunixin</td>
<td>Flunixin</td>
<td>Bovine</td>
<td>20 µg/kg</td>
<td>Muscle</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>30 µg/kg</td>
<td>Fat</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>300 µg/kg</td>
<td>Liver</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>100 µg/kg</td>
<td>Kidney</td>
</tr>
<tr>
<td></td>
<td>5-hydroxy flunixin</td>
<td>Bovine</td>
<td>40 µg/kg</td>
<td>Milk</td>
</tr>
<tr>
<td>Flunixin</td>
<td>Flunixin</td>
<td>Porcine</td>
<td>50 µg/kg</td>
<td>Muscle</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>10 µg/kg</td>
<td>Skin+Fat</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>200 µg/kg</td>
<td>Liver</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>30 µg/kg</td>
<td>Kidney</td>
</tr>
<tr>
<td>Flunixin</td>
<td>Flunixin</td>
<td>Equidae</td>
<td>10 µg/kg</td>
<td>Muscle</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>20 µg/kg</td>
<td>Fat</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>100 µg/kg</td>
<td>Liver</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>200 µg/kg</td>
<td>Kidney</td>
</tr>
</tbody>
</table>

Withdrawal Periods

Based on the data provided above, the following withdrawal periods are justified:

Cattle: Meat: 14 days
Milk: 2 days
Horses: Meat: 28 days
Do not use in horses producing milk for human consumption
Pigs: Meat: 28 days
IV. CLINICAL ASSESSMENT (EFFICACY)

As this is a generic application according to Article 13, and bioequivalence with a reference product has been demonstrated, efficacy studies are not required. The efficacy claims for this product are equivalent to those of the reference product.

Nevertheless, Fluvex is recommended to use in sows by intramuscular injection. The recommended method of administration for Finadyn in this target specie is intravenous injection. So the applicant includes a bioequivalence study of Solution injectable of Flunixin (meglumine) 5% and Reference item (Finadyne) in sows.

A local tolerance study in sows has been provided to demonstrate the good tolerance Fluvex shows by this method of administration.

IV.A Pre-Clinical Studies

Pharmacology

The applicant has conducted a bioequivalence study to show that the test item (Fluvex) and the reference product (Finadyn) are bioequivalent when administered in sows.

A two period, two treatments two sequence crossover study was conducted in 16 healthy sows distributed into two groups. Plasma levels of Flunixin were determined at pre-established post-administration times.

The bioequivalence was determined by calculating the confidence limits of the difference of the two means.

According to requirements provided by Guideline EMEA/CVMP/016/00-Final Guidelines for the conduct of the bioequivalence study for veterinary medicinal products, both products were demonstrated bioequivalent.

Tolerance in the Target Species of Animals

The applicant has conducted a controlled target animal tolerance study using the recommended dose in the target species. A placebo was used as a control. All doses were administered by intramuscular route twice (separated 12 hours).

Parameters evaluated were body weights (twice a week and the same day of the administration), injection sites (twice a week until the day of sacrifice, looking for macroscopic lesions, pain or suffering), CPK levels (at the following times after the last treatment: 1, 6, 12, 24 and 96 hours and 7, 16 and 21 days).

Injection site samples were dissected after sacrifice and macro/microscopically evaluated by a pathologist looking for signs of lesions.

Minimal adverse effects were seen following the recommended dose. There were necrotising lesions (acute lesions) at the application sites that evolved to chronic lesions (replacement of...
the necrotic tissue with granulation tissue). These lesions were well-related to the administration of the test item. These local muscular lesions recovered with time.

The product literature accurately reflects the type and incidence of adverse effects which might be expected.

**IV.B Clinical Studies**

*This is a generic application according to Article 13 (1) of Directive 2001/82/EC as amended, based on the essential similarity of Fluvex and the reference product FINADYN solution for injection (Schering Plough S.A.)*

*The applicant is therefore exempted from presenting clinical studies.*
V. OVERALL CONCLUSION AND BENEFIT- RISK ASSESSMENT

The data submitted in the dossier demonstrate that when the product is used in accordance with the Summary of Product Characteristics, the risk benefit profile for the target species is favourable and the quality and safety of the product for humans and the environment is acceptable.
POST-AUTHORISATION ASSESSMENTS

The SPC and package leaflet may be updated to include new information on the quality, safety and efficacy of the veterinary medicinal product. The current SPC is available on the veterinary Heads of Agencies website (www.hma.eu).

This section contains information on significant changes which have been made after the original procedure which are important for the quality, safety or efficacy of the product.

None